47 results
10-Q
2024 Q1
EX-31.2
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations … information; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws; or laws that require the reporting of financial information
10-Q
2024 Q1
EX-31.1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant
POS AM
EX-5.1
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
(opschorting), dissolution (ontbinding), unforeseen circumstances (onvoorziene omstandigheden) and vitiated consent (i.e., duress (bedreiging), fraud (bedrog
POS AM
EX-5.1
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
), fraud (bedrog), abuse of circumstances (misbruik van omstandigheden) and error (dwaling)) or a difference of intention (wil) and declaration (verklaring
10-K
EX-10.7
ap5tsp8 qy0f8tyqp3
28 Feb 24
Annual report
8:00am
10-K
3pabswr47rey6gw sg8
28 Feb 24
Annual report
8:00am
10-K
EX-10.9
86vlvyujusf 09y6k
28 Feb 24
Annual report
8:00am
10-K
EX-31.2
4l4hj 5ir
28 Feb 24
Annual report
8:00am
10-K
EX-10.8
mkhtwj
28 Feb 24
Annual report
8:00am
10-K
EX-10.4
osn6183
28 Feb 24
Annual report
8:00am
10-K
EX-31.1
vw2b8igv
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
hv90 xsicfui
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
8-K
EX-5.1
bejwa45eg9fr
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
F-3
EX-5.1
hb2w8hl26w klw
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-1.2
xy8ownx1y8h7ps0 td
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
91v1ztl36 bc7
15 Aug 23
Prospectus supplement
4:52pm
POS AM
ulopoek zdqeo7xzpt
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
z24n5
7 Aug 23
Research and development expenses
7:24am
424B3
oydsihhobu82 duuh5
9 Jun 23
Prospectus supplement
9:43pm